FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202564256> ?p ?o ?g. }

• W3202564256 abstract "Abstract Age related macular degeneration (AMD) is the most common cause of vision loss in the elderly population. Neovascular AMD comprises 10% of all cases and can lead to devastating visual loss due to choroidal neovascularization (CNV). There are various cytokine pathways involved in the formation and leakage from CNV. Prior treatments have included focal laser therapy, verteporfin (Visudyne, Bausch and Lomb, Rochester, New York) ocular photodynamic therapy, transpupillary thermotherapy, intravitreal steroids and surgical excision of choroidal neovascular membranes. Currently, the major therapies in AMD focus on the VEGF-A pathway, of which the most common are bevacizumab (Avastin; Genentech, San Francisco, California), ranibizumab (Lucentis; Genentech, South San Francisco, California), and aflibercept (Eylea; Regeneron, Tarrytown, New York). Anti-VEGF agents have revolutionized our treatment of wet AMD; however, real world studies have shown limited visual improvement in patients over time, largely due to the large treatment burden. Cheaper alternatives, including ranibizumab biosimilars, include razumab (Intas Pharmaceuticals Ltd., Ahmedabad, India), FYB 201 (Formycon AG, Munich, Germany and Bioeq Gmbh Holzkirchen, Germany), SB-11 (Samsung Bioepsis, Incheon, South Korea), xlucane (Xbrane Biopharma, Solna, Sweden), PF582 (Pfnex, San Diego, California), CHS3551 (Coherus BioSciences, Redwood City, California). Additionally, aflibercept biosimilars under development include FYB203 (Formycon AG, Munich, Germany and Bioeq Gmbh Holzkirchen, Germany), ALT-L9 (Alteogen, Deajeon, South Korea), MYL1710 (Momenta Pharamaceuticals, Cambridge, MA, and Mylan Pharmacueticals, Canonsburg, PA), CHS-2020 (Coherus BioSciences, Redwood City, California). Those in the pipeline of VEGF targets include abicipar pegol (Abicipar; Allergan, Coolock, Dublin), OPT-302 (Opthea; OPTHEA limited; Victoria, Melbourne), conbercept (Lumitin; Chengdu Kanghong Pharmaceutical Group, Chengdu, Sichuan), and KSI-301 (Kodiak Sciences, Palo Alto, CA). There are also combination medications, which target VEGF and PDGF, VEGF and tissue factor, VEGF and Tie-2, which this paper will also discuss in depth. Furthermore, long lasting depots, such as the ranibizumab port delivery system (PDS) (Genentech, San Francisco, CA), as well as others are under evaluation. Gene therapy present possible longer treatments options as well and are reviewed here. This paper will highlight the past approved medications as well as pipeline therapies for neovascular AMD." @default.
• W3202564256 created "2021-10-11" @default.
• W3202564256 creator A5019125791 @default.
• W3202564256 creator A5050007384 @default.
• W3202564256 date "2021-10-01" @default.
• W3202564256 modified "2023-10-16" @default.
• W3202564256 title "Pipeline therapies for neovascular age related macular degeneration" @default.
• W3202564256 cites W1487528435 @default.
• W3202564256 cites W1500728559 @default.
• W3202564256 cites W1755815992 @default.
• W3202564256 cites W1842385511 @default.
• W3202564256 cites W1980725734 @default.
• W3202564256 cites W1983763042 @default.
• W3202564256 cites W1992955876 @default.
• W3202564256 cites W2003324689 @default.
• W3202564256 cites W2004117352 @default.
• W3202564256 cites W2028808241 @default.
• W3202564256 cites W2029761910 @default.
• W3202564256 cites W2043873545 @default.
• W3202564256 cites W2052204551 @default.
• W3202564256 cites W2075634939 @default.
• W3202564256 cites W2080230141 @default.
• W3202564256 cites W2081023310 @default.
• W3202564256 cites W2085712747 @default.
• W3202564256 cites W2091989599 @default.
• W3202564256 cites W2095317976 @default.
• W3202564256 cites W2095577723 @default.
• W3202564256 cites W2124415048 @default.
• W3202564256 cites W2134161293 @default.
• W3202564256 cites W2160226180 @default.
• W3202564256 cites W2188870890 @default.
• W3202564256 cites W2412590065 @default.
• W3202564256 cites W2530096473 @default.
• W3202564256 cites W2543150770 @default.
• W3202564256 cites W2554058929 @default.
• W3202564256 cites W2589033892 @default.
• W3202564256 cites W2592326023 @default.
• W3202564256 cites W2615193664 @default.
• W3202564256 cites W2619267093 @default.
• W3202564256 cites W2621250360 @default.
• W3202564256 cites W2740090310 @default.
• W3202564256 cites W2804349267 @default.
• W3202564256 cites W2888207742 @default.
• W3202564256 cites W2898444405 @default.
• W3202564256 cites W2933377962 @default.
• W3202564256 cites W2936430874 @default.
• W3202564256 cites W2958724362 @default.
• W3202564256 cites W2962115070 @default.
• W3202564256 cites W2981587847 @default.
• W3202564256 cites W2989989541 @default.
• W3202564256 cites W2990916334 @default.
• W3202564256 cites W2994865070 @default.
• W3202564256 cites W3015836115 @default.
• W3202564256 cites W3017504588 @default.
• W3202564256 cites W3033555223 @default.
• W3202564256 cites W3036312458 @default.
• W3202564256 cites W3037628349 @default.
• W3202564256 cites W3046426723 @default.
• W3202564256 doi "https://doi.org/10.1186/s40942-021-00325-5" @default.
• W3202564256 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8485527" @default.
• W3202564256 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34598731" @default.
• W3202564256 hasPublicationYear "2021" @default.
• W3202564256 type Work @default.
• W3202564256 sameAs 3202564256 @default.
• W3202564256 citedByCount "17" @default.
• W3202564256 countsByYear W32025642562021 @default.
• W3202564256 countsByYear W32025642562022 @default.
• W3202564256 countsByYear W32025642562023 @default.
• W3202564256 crossrefType "journal-article" @default.
• W3202564256 hasAuthorship W3202564256A5019125791 @default.
• W3202564256 hasAuthorship W3202564256A5050007384 @default.
• W3202564256 hasBestOaLocation W32025642561 @default.
• W3202564256 hasConcept C118487528 @default.
• W3202564256 hasConcept C141071460 @default.
• W3202564256 hasConcept C2776403814 @default.
• W3202564256 hasConcept C2776694085 @default.
• W3202564256 hasConcept C2777802072 @default.
• W3202564256 hasConcept C2778749236 @default.
• W3202564256 hasConcept C2781100027 @default.
• W3202564256 hasConcept C2781148688 @default.
• W3202564256 hasConcept C2781359195 @default.
• W3202564256 hasConcept C71924100 @default.
• W3202564256 hasConceptScore W3202564256C118487528 @default.
• W3202564256 hasConceptScore W3202564256C141071460 @default.
• W3202564256 hasConceptScore W3202564256C2776403814 @default.
• W3202564256 hasConceptScore W3202564256C2776694085 @default.
• W3202564256 hasConceptScore W3202564256C2777802072 @default.
• W3202564256 hasConceptScore W3202564256C2778749236 @default.
• W3202564256 hasConceptScore W3202564256C2781100027 @default.
• W3202564256 hasConceptScore W3202564256C2781148688 @default.
• W3202564256 hasConceptScore W3202564256C2781359195 @default.
• W3202564256 hasConceptScore W3202564256C71924100 @default.
• W3202564256 hasFunder F4320308320 @default.
• W3202564256 hasIssue "1" @default.
• W3202564256 hasLocation W32025642561 @default.
• W3202564256 hasLocation W32025642562 @default.
• W3202564256 hasLocation W32025642563 @default.
• W3202564256 hasOpenAccess W3202564256 @default.
• W3202564256 hasPrimaryLocation W32025642561 @default.
• W3202564256 hasRelatedWork W2012546470 @default.

• next